880432--9/28/2006--MISONIX_INC

related topics
{property, intellectual, protect}
{product, liability, claim}
{product, market, service}
{product, candidate, development}
{regulation, government, change}
{financial, litigation, operation}
{operation, international, foreign}
{cost, operation, labor}
Risks Related to Our Business We are subject to extensive medical device regulation which may impede or hinder the approval process for our products and, in some cases, may not ultimately result in approval or may result in the recall or seizure of previously approved products. We may not meet regulatory quality standards applicable to our manufacturing and quality processes, which could have an adverse effect on our business, financial condition or results of operations. Future intellectual property litigation could be costly and disruptive to us. We may not be able effectively to protect our intellectual property rights which could have an adverse effect on our business, financial condition or results of operations. Future product liability claims and other litigation, including private securities litigation and shareholder derivative suits, may adversely affect our business, reputation and ability to attract and retain customers. We may not be successful in our strategic initiatives to become primarily a medical device company. Our future growth is dependent upon the development of new products, which requires significant research and development, clinical trials and regulatory approvals, all of which are very expensive and time-consuming and may not result in a commercially viable product. We face intense competition and may not be able to keep pace with the rapid technological changes in the medical devices industry, which could have an adverse effect on our business, financial condition or results of operations. Because we derive a significant amount of our revenues from international operations and a significant percentage of our growth is expected to come from international operations, changes in international economic or regulatory conditions could have a material impact on our business, financial condition or results of operations. Consolidation in the healthcare industry could lead to demands for price concessions or the exclusion of some suppliers from certain of our significant market segments, which could have an adverse effect on our business, financial condition or results of operations.

Full 10-K form ▸

related documents
880432--9/28/2009--MISONIX_INC
1114200--2/27/2008--AMERICAN_MEDICAL_SYSTEMS_HOLDINGS_INC
874734--3/12/2008--OSTEOTECH_INC
27096--9/12/2007--DATASCOPE_CORP
1101026--5/18/2009--HEALTH_ENHANCEMENT_PRODUCTS_INC
10456--2/26/2008--BAXTER_INTERNATIONAL_INC
1029023--3/2/2009--SYNTROLEUM_CORP
1114200--3/1/2010--AMERICAN_MEDICAL_SYSTEMS_HOLDINGS_INC
350692--12/28/2007--DELPHAX_TECHNOLOGIES_INC
1110783--11/2/2006--MONSANTO_CO_/NEW/
28626--9/13/2007--LIFECORE_BIOMEDICAL_INC
55242--8/16/2007--KENNAMETAL_INC
880432--9/26/2008--MISONIX_INC
59527--2/24/2009--LINCOLN_ELECTRIC_HOLDINGS_INC
718924--12/28/2007--SPAN_AMERICA_MEDICAL_SYSTEMS_INC
1009672--3/2/2009--CARBO_CERAMICS_INC
20--3/9/2007--K_TRON_INTERNATIONAL_INC
805305--1/12/2007--QUIKSILVER_INC
805305--12/30/2008--QUIKSILVER_INC
54441--3/17/2008--FURMANITE_CORP
912093--8/31/2010--JDS_UNIPHASE_CORP_/CA/
806517--3/27/2009--PSYCHEMEDICS_CORP
1129096--10/28/2009--INFITECH_VENTURES_INC
853695--3/31/2009--DRI_CORP
916459--2/29/2008--GARDNER_DENVER_INC
1116463--3/10/2009--ORASURE_TECHNOLOGIES_INC
758004--5/25/2007--NOVELL_INC
883107--3/14/2007--NANOPHASE_TECHNOLOGIES_CORPORATION
853695--3/28/2007--DIGITAL_RECORDERS_INC
780127--1/7/2009--SYNOVIS_LIFE_TECHNOLOGIES__INC